pipette
ESEspañol

Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies

Cody Fell, Anthony E. Davis, Shalini Pandey, Michael Tyler Guinn, Zeshi Wang, Jonathon DeBonis, Chancellor Smith, Nathan Brown, Danna Murungi, 김연주, Imaan Mohandessi, Patrick Bednarz, Amir Ardeshir, Erin M. Haupt, Samuel Cuevas, Christy L. Lavine, Michael S. Seaman, Oleg A. Igoshin, Ravi K. Ghanta, Michael R. Diehl, Omid Veiseh

Peer-reviewed journalBold claims, read criticallyClaims a big stepReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Here, we developed an immunomodulatory, encapsulated cell–based “biologics factory” that overcomes mAb instability, immunogenicity, and the fibrotic foreign body response that have limited previous approaches, enabling continuous in situ production of therapeutic antibodies from a single administration.

Appeared: Sunday, October 4. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aej5440